This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Idaho
Licensed Idaho practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Idaho buyers need their own professional license and NPI; the wholesale distributor license is the supplier’s obligation, not the purchaser’s.
Idaho runs every relevant board through a single umbrella agency, the Division of Occupational and Professional Licenses, and its nurse practitioners have practiced without physician supervision since 2004, among the earliest such dates in the country. The statute visitors most often ask about, the Right to Try Act, reaches terminally ill patients and investigational products, which is worth understanding precisely because it does not reach aesthetic practice.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Idaho? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Idaho
ExaVeyra ships to licensed practices in all 50 states, Idaho included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Idaho professional license in good standing, verifiable through the Division of Occupational and Professional Licenses online license search.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- An Idaho seller’s permit and the Sales Tax Resale or Exemption Certificate (form ST-101) if the practice is purchasing for resale rather than for use in its own operations, filed through the State Tax Commission.
How the state permits wholesale distribution
Idaho licenses wholesale distributors through the Board of Pharmacy, within the Division of Occupational and Professional Licenses, and the statute is written at the shipping event: every business entity that engages in the wholesale distribution of prescription drugs, durable medical equipment, or pseudoephedrine products in or into Idaho is licensed by the Board, a scope that reaches durable medical equipment where most states stop at prescription drugs. Nonresident facilities register under Idaho Code 54-1729 and must be licensed and in good standing in their home state, submit to inspections, and keep a designated representative involved in daily operations. The license sits with the distributor, not with the purchasing practice.
Idaho Code §§ 54-1729, 54-1729A · Idaho Board of Pharmacy, Division of Occupational and Professional Licenses
Idaho regenerative-medicine law
Idaho has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No Idaho statute addresses unapproved regenerative therapy, so federal law is the only layer. The nearest neighbor in the code is the Right to Try Act, Idaho Code title 39, chapter 94, enacted in 2016, which lets a terminally ill patient request an investigational drug, biological product, or device from its manufacturer under a treating physician. That act is about end-stage disease and products already in formal development; it neither authorizes nor conditions elective or aesthetic practice. Practice in this area is governed by the Medical Practice Act, the Nursing Practice Act, and the boards within the Division of Occupational and Professional Licenses, alongside federal law.
How this applies to exosomes
Idaho has no stem cell authorization law like Florida, Texas, or Georgia, no disclosure law like California, and no documentation statute like Tennessee. Its Right to Try Act is sometimes raised in this context, and the comparison is instructive: that act reaches terminally ill patients receiving investigational products from manufacturers under a treating physician, a situation with nothing in common with an aesthetic practice ordering supplier material. There is no Idaho definition to read exosomes into or out of, and exosomes are acellular extracellular vesicles in any case. Exosome products in Idaho are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Idaho practice
Because advanced practice registered nurses hold independent authority in Idaho, there are two workable structures rather than one. An APRN-led practice can evaluate and order within APRN scope, an arrangement two decades old here rather than a recent change. A physician-led practice delegates conventionally, and a medical director is still needed where a procedure falls outside APRN scope or where a payer requires one. The Boards of Medicine, Nursing, and Pharmacy all sit within the Division of Occupational and Professional Licenses, so license verification runs through a single agency.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians and osteopathic physicians licensed by the Idaho Board of Medicine may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. |
| NP / APRN | Idaho advanced practice registered nurses are licensed by the Board of Nursing under Idaho Code 54-1409 and practice without a physician supervision or collaboration requirement, which Idaho removed in 2004. An APRN-led practice can evaluate, order, and prescribe within its own scope, with the Board’s peer review expectations in place of supervision paperwork. |
| PA | Physician assistants are licensed by the Idaho Board of Medicine and practice in collaboration with physicians, with the collaborative details set at the practice level under the Board’s current rules rather than through a filed supervisory agreement. |
| RN | Registered nurses may perform delegated treatments within their scope and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Idaho expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Where an advanced practice registered nurse holds independent authority, that provider can be the APRN. Confirm current expectations with the Idaho Board of Medicine and the Idaho Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Idaho does not codify a corporate practice of medicine prohibition in statute. Older Idaho case law is sometimes cited for a corporate practice doctrine, and published summaries disagree about its modern force, so the honest answer is that professional entities and management services arrangements are the usual structures and that ownership structure here is a question for Idaho counsel rather than one a guide should answer with a bright-line rule.
Cold chain into Idaho
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Idaho order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Boise | Ada | Largest Idaho market, with the state’s deepest aesthetic and clinical coverage. |
| Meridian | Ada | Fast-growing Treasure Valley suburb served alongside Boise. |
| Coeur d’Alene | Kootenai | North Idaho market serving the Spokane border corridor. |
| Idaho Falls | Bonneville | Eastern Idaho hub with a regional medical center. |
| Twin Falls | Twin Falls | Magic Valley market serving south-central Idaho. |
| Ketchum and Sun Valley | Blaine | Resort market with orthopedic and sports medicine concentration. |
- Idaho orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every shipment arrives with the manufacturer’s handling instructions and the Certificate of Analysis for its lot.
Wholesale exosome supply by city in Idaho
Each city page covers local receiving conditions, delivery disruptions and business license rules for Idaho practices in that area.
Practice types we supply in Idaho
Idaho licensing and verification
Idaho Board of Medicine (DOPL)
Licenses physicians, osteopathic physicians, and physician assistants.
Idaho Board of Nursing (DOPL)
Licenses RNs, LPNs, and APRNs; APRNs practice without a supervision requirement.
Idaho Board of Pharmacy (DOPL)
Licenses the wholesale distributors that ship prescription drugs in or into Idaho.
Idaho State Tax Commission
Seller’s permits and the ST-101 resale or exemption certificate.
Idaho sourcing questions
- Does Idaho have a stem cell law?
- No. Idaho has no stem cell authorization law, disclosure law, or documentation statute. The Right to Try Act, Idaho Code title 39, chapter 94, is sometimes mistaken for one: it lets terminally ill patients request investigational products from manufacturers under a treating physician, and it neither authorizes nor conditions elective or aesthetic practice. Exosome products in Idaho are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification saying so. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- Can a nurse practitioner run a practice in Idaho without a physician?
- Yes, within APRN scope. Idaho removed the physician supervision requirement for nurse practitioners in 2004, among the earliest states to do so, and APRNs are licensed by the Board of Nursing with independent prescriptive authority and a biennial peer review expectation in place of supervision paperwork. A medical director is still needed where a procedure falls outside APRN scope or where a payer requires one.
- Does my Idaho clinic need a wholesale distributor license to buy exosomes?
- No. The wholesale distributor license under Idaho Code 54-1729A is held by the business entity distributing in or into Idaho, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- What is distinctive about Idaho’s wholesale statute?
- Two things. It is written at the shipping event, reaching wholesale distribution in or into Idaho, so out-of-state shippers are squarely inside it, and its subject list is broader than most states’, covering prescription drugs, durable medical equipment, and pseudoephedrine products. Nonresident facilities also register with the Board of Pharmacy and must be licensed and in good standing in their home state.
- How long does cold-chain shipping take to Idaho?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Idaho Code § 54-1729A, wholesale drug distributor licensure (accessed 16 October 2026)
- Idaho Code § 54-1729, registration and licensure of facilities (accessed 16 October 2026)
- Idaho Board of Pharmacy (DOPL) (accessed 16 October 2026)
- Idaho Code title 39, chapter 94, Right to Try Act (accessed 16 October 2026)
- Idaho Board of Medicine (DOPL) (accessed 16 October 2026)
- Idaho Board of Nursing (DOPL) (accessed 16 October 2026)
- Idaho State Tax Commission (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The field’s current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page says accompanies every Idaho order.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark EV characterization standard that MISEV2023 updates; together they define what a complete exosome characterization package contains, the documentation standard this page describes.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: ISEV position on manufacturing and safety documentation for EV-based products in trials, supporting this page’s framing that clinical use of exosomes runs through regulated research, the same line the Right to Try discussion draws.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.